Immune-Related Adverse Events of Tislelizumab in 120 Patients with Hepatocellular Carcinoma

doi:10.19803/j.1672-8629.20240987

Abstract

Abstract: Objective To analyze the characteristics of immune-related adverse events (irAEs) of tislelizumab in patients with hepatocellular carcinoma and provide data for safe clinical use of the drug. Methods The irAEs caused by tislelizumab in the treatment of patients with liver cancer in Guangxi Zhuang Autonomous Region from February 2022 to June 2024 were collected. The data on gender of the patients, age distribution, indications for use, concomitant medications, clinical manifestations, toxicity grading, treatments, outcomes, and the characteristics of irAEs was statistically analyzed. Results A total of 120 cases of irAEs were collected. There were four times as many male patients as female ones, and most of the patients ranged from 45 to 64 in age. The systems and organs involved in irAEs were mostly the blood system, liver system and the skin system. There were 61 cases (50.83%) of irAEs ≥G3, but no death due to G5 irAEs occurred. Seventy-eight patients (65%) showed improvement or recovery after symptomatic treatment. Conclusion Although irAEs caused by tislelizumab involve multiple systems and organs, most patients have good outcomes if treated promptly. During clinical use of tislelizumab, irAEs should be detected as early as possible, and precautions have to be taken to ensure the safety and health of patients.

Key words: Tislelizumab, Immune-related Adverse Events, Hepatocellular Carcinoma, Immune Checkpoint Inhibitors, Blood System, Liver System, Skin System

CLC Number:

LIANG Fanglin, CHEN Lingyuan, HU Danli, WEI Lingyun, WEI Tiemeng, ZHANG Faen, WEI Yana. Immune-Related Adverse Events of Tislelizumab in 120 Patients with Hepatocellular Carcinoma[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 659-663.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240987

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I6/659

References

[1] SUNG H, FERLAY J, SIEGEL RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA: a Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[2] NAN Y, MIAO T.Advances in Targeted and Immune Therapies for Hepatocellular Carcinoma[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2022, 30(9): 905-911.
[3] REIG M, FORNER A, RIMOLA J, et al.BCLC Strategy for Prognosis Prediction and Treatment Recommendation: the 2022 Update[J]. Journal of Hepatology, 2022, 76(3): 681-693.
[4] LLOVET JM, CASTET F, HEIKENWALDER M, et al.Immunoth-erapies for Hepatocellular Carcinoma[J]. Nature Reviews. Clinical Oncology, 2022, 19(3): 151-172.
[5] CHEN S, SHUANGYAN T, SHI F, et al.TACE Plus Lenvatinib and Tislelizumab for Intermediate-Stage Hepatocellular Carcinoma beyond up-to-11 Criteria: a Multicenter Cohort Study[J]. Frontiers in Immunology, 2024, 15: 1430571.
[6] BORGEAUD M, SANDOVAL J, OBEID M, et al.Novel Targets for Immune-Checkpoint Inhibition in Cancer[J]. Cancer Treatment Reviews, 2023, 120: 102614.
[7] MACEK JILKOVA Z, ASPORD C, DECAENS T.Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges[J]. Cancers, 2019, 11(10): 1554.
[8] LEE A, KEAM SJ.Tislelizumab: First Approval[J]. Drugs, 2020, 80(6): 617-624.
[9] YI L, QING L, LIN H.A Programmed Death Receptor-1 Inhibitor-Tislelizumab[J]. Clinical Medication Journal(临床药物治疗杂志), 2022, 20(1): 37-42.
[10] RAMOS-CASALS M, BRAHMER JR, CALLAHAN MK, et al.Immune-Related Adverse Events of Checkpoint Inhibitors[J]. Nature Reviews Disease Primers, 2020, 6(1): 38.
[11] SHIRAVAND Y, KHODADADI F, KASHANI SMA, et al.Immune Checkpoint Inhibitors in Cancer Therapy[J]. Current Oncology, 2022, 29(5): 3044-3060.
[12] SULLIVAN RJ, WEBER JS.Immune-Related Toxicities of Checkpoint Inhibitors: Mechanisms and Mitigation Strategies[J]. Nature Reviews Drug Discovery, 2022, 21(7): 495-508.
[13] ZHANG J, ZHANG LL, LI X.Analysis of Immune-Related Adverse Events of Tirelizumab in 424 Cases of Cancer Patients[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(4): 435-439.
[14] National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE 5.0)[EB/OL]. (2017-11-27)[2023-10-15]. http://guide. medlive.cn/.
[15] NEVOLA R, TORTORELLA G, ROSATO V, et al.Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma[J]. Biology, 2023, 12(7): 984.
[16] WU EM, WONG LL, HERNANDEZ BY, et al.Gender Differences in Hepatocellular Cancer: Disparities in Nonalcoholic Fatty Liver Disease/Steatohepatitis and Liver Transplantation[J]. HEPATOLOGY RESEARCH, 2018, 4: 66.
[17] BRAY F, LAVERSANNE M, SUNG H, et al.Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA: A Cancer Journal for Clinicians, 2024, 74(3): 229-263.
[18] RICH NE, YOPP AC, SINGAL AG, et al.Hepatocellular Carcinoma Incidence Is Decreasing among Younger Adults in the United States[J]. Clinical Gastroenterology and Hepatology, 2020, 18(1): 242-248.
[19] REDDY KR, MCLERRAN D, MARSH T, et al.Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: the Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study[J]. Gastroenterology, 2023, 165(4): 1053-1063.
[20] SHEN L, YL W.Preliminary Results of a Phase 1/2 Study of BGB-A317, an Anti-PD1 mAb in Chinese Patients with Advanced Tumors[C]. 20th Annual Chinese Society for Clinical Oncology, 2017: 26-30.
[21] XU L, CHEN J, LIU C, et al.Efficacy and Safety of Tislelizumab Plus Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma: a Multicenter, Single-Arm, Phase 2 Trial[J]. BMC Medicine, 2024, 22(1): 172.
[22] REN X, TIAN Y, WANG Z, et al.Tislelizumab in Combination with Gemcitabine Plus Cisplatin Chemotherapy as First-Line Adjuvant Treatment for Locally Advanced or Metastatic Bladder Cancer: a Retrospective Study[J]. BMC Urology, 2022, 22(1): 128.
[23] LI L, LI G, RAO B, et al.Landscape of Immune Checkpoint Inhibitor-Related Adverse Events in Chinese Population[J]. Scientific Reports, 2020, 10(1): 15567.
[24] ZHANG L, GENG Z, HAO B, et al.Tislelizumab: a Modified Anti-Tumor Programmed Death Receptor 1 Antibody[J]. Cancer Control, 2022, 29: 1-14.
[25] QIN S, FINN R S, KUDO M, et al.RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepato-cellular Carcinoma[J]. Future Oncology, 2019, 15(16): 1811-1822.
[26] FESSAS P, POSSAMAI L A, CLARK J, et al.Immunotoxicity from Checkpoint Inhibitor Therapy: Clinical Features and Underlying Mechanisms[J]. Immunology, 2020, 159(2): 167-177.
[27] GEISLER AN, PHILLIPS GS, BARRIOS DM, et al.Immune Checkpoint Inhibitor-Related Dermatologic Adverse Events[J]. Journal of the American Academy of Dermatology, 2020, 83(5): 1255-1268.
[28] YIN Q, WU L, HAN L, et al.Immune-Related Adverse Events of Immune Checkpoint Inhibitors: a Review[J]. Frontiers in Immun-ology, 2023, 14: 1167975.
[29] JOHNSON DB, NEBHAN CA, MOSLEHI JJ, et al.Immune-Checkpoint Inhibitors: Long-Term Implications of Toxicity[J]. Nature Reviews. Clinical Oncology, 2022, 19(4): 254-267.
[30] VARRICCHI G, GALDIERO MR, MARONE G, et al.Cardiotoxicity of Immune Checkpoint Inhibitors[J]. ESMO Open, 2017, 2(4): e000247.
[31] MAHMOOD SS, FRADLEY MG, COHEN JV, et al.Myocarditis in Patients Treated with Immune Checkpoint Inhibitors[J]. Journal of the American College of Cardiology, 2018, 71(16): 1755-1764.
[32] JOHNSON DB, MANOUCHEHRI A, HAUGH AM, et al.Neurologic Toxicity Associated with Immune Checkpoint Inhibitors: a Pharm-acovigilance Study[J]. Journal for Immunotherapy of Cancer, 2019, 7: 1-9.